Delivery Order SPE2DB24D2012-SPE2DB25FBWNT
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,537.84 firm fixed price delivery order on July 29, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 30, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and running through December 2026. The product will be delivered to the...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,007.80 for NovoLog 100 Unit/ML FlexPen 3ML insulin pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract for pharmaceutical supply to support federal medical needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for military...
- The Defense Logistics Agency awarded a delivery order valued at $4,917.74 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitively awarded, firm fixed-price delivery order was issued on July 31, 2025, with an ultimate completion date of August 1, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a small-value transaction within AmerisourceBergen's broader federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $1,257.27 with a firm fixed price structure. The award, issued on July 30, 2025, represents a non-competitive delivery order with a completion date of July 31, 2025. This contract is a child award executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999.00 comprehensive...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,392.51 for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on July 28, 2025, with completion targeted for July 29, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a small-value pharmaceutical procurement to support federal medical supply requirements. The delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken,...
- The Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $5,751.48 for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order represents a competitive, non-set-aside award to supply pharmaceutical products supporting federal military and veteran healthcare systems. The work will be performed at AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $20,440.89 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on July 30, 2025, with a completion date of July 31, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to supply insulin medication to support federal healthcare needs. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $3,682.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 22, 2025. This non-set-aside competitive award will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. This delivery order executes under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, a diabetes medication used across military healthcare systems. This firm fixed price delivery order, valued at $1,686.96, was competitively awarded without set-aside designation and is scheduled for completion by August 1, 2025. The product will be delivered to AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a $8,495.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a completion date of July 21, 2025. This non-set-aside contract was competitively awarded on July 18, 2025, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal healthcare needs, specifically for diabetes...
- SPE2DB24D2012Indefinite Delivery Contract
- SPE2DB24D2012-SPE2DB25FBWNTDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,405.80 for NovoLog 100 Unit/ML FlexPen 3ML, a insulin medication used in diabetes management. Issued on July 29, 2025, with an ultimate completion date of July 30, 2025, this firm fixed price delivery order represents a competitive award with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As a prime vendor under this IDC, AmerisourceBergen supplies a broad range of pharmaceuticals and medical supplies to support military healthcare programs and other federal healthcare systems worldwide, including the Defense Health Agency and U.S. Coast Guard. The company's role as a major pharmaceutical distributor and critical federal medical procurement vendor reflects its established capability to meet defense supply chain requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 7/29/25 |